# US 2026/0232839 A1 · Lipid Nanoparticle, Pharmaceutical Composition, and Method for Producing Lipid Nanoparticle

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0232839 A1
- Document ID: US20260232839A1
- Status: Published application
- Kind: A1
- Application number: 19/158,928
- Filed: 2024-03-04
- Published: 2026-08-13
- Earliest claimed: 2023-03-02
- Assignees: Japan Science and Technology Agency
- Applicants: Japan Science and Technology Agency
- Inventors: Yoshimasa Kawaguchi; Shiroh Futaki; Yusuke Hirai; Hisaaki Hirose; Chisato Kasahara
- Web page: https://patentgrep.com/patent/US20260232839A1

## CPC

- A61K 47/6935: {the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol}
- A61P 35/00: Antineoplastic agents
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 9/5192: {Processes}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A61K 39/39591: {Stabilisation, fragmentation}
- C07K 16/18: against material from animals or humans
- C07K 16/40: against enzymes
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/80: remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure is a lipid nanoparticle including a composition including a protein selected from an antibody and an antibody fragment, a polymer, and a lipid, in which the polymer and the protein have opposite charges at a predetermined pH. The lipid nanoparticle preferably has a protein encapsulated therein. In addition, when the particle diameter of the lipid nanoparticles is measured, the peak top of the particle diameter distribution is preferably at 80 nm to 120 nm.

## Claims

### Claim 1

A lipid nanoparticle comprising a composition comprising a protein selected from an antibody and an antibody fragment, a polymer, and a lipid, wherein the protein and the polymer have opposite charges at a predetermined pH.

### Claim 2 (depends on 1)

The lipid nanoparticle according to claim 1, wherein the protein is encapsulated in the lipid nanoparticle.

### Claim 3 (depends on 1)

The lipid nanoparticle according to claim 1, wherein a peak top of a particle diameter distribution is at 80 nm to 120 nm when a particle diameter of the lipid nanoparticle is measured.

### Claim 4 (depends on 1)

The lipid nanoparticle according to claim 1, wherein the polymer is an anionic or cationic polymer.

### Claim 5 (depends on 4)

The lipid nanoparticle according to claim 4, wherein the cationic polymer is at least one selected from the group consisting of polylysine, polyarginine, polyhistidine, and water-soluble salts thereof.

### Claim 6 (depends on 4)

The lipid nanoparticle according to claim 4, wherein the anionic polymer is at least one polyamino acid selected from the group consisting of polyglutamic acid and polyaspartic acid, or at least one glycosaminoglycan selected from the group consisting of hyaluronic acid and pullulan.

### Claim 7 (depends on 4)

The lipid nanoparticle according to claim 4, wherein the cationic or anionic polymer has a molecular weight of 0.5 kDa to 1,000 kDa.

### Claim 8 (depends on 1)

The lipid nanoparticle according to claim 1, wherein the lipid is a cationic lipid.

### Claim 9 (depends on 1)

The lipid nanoparticle according to claim 1, further comprising one or more lipids selected from the group consisting of a neutral phospholipid, a PEG lipid, and cholesterol.

### Claim 10

A pharmaceutical composition comprising a composition comprising a protein selected from an antibody and an antibody fragment, a polymer, and a lipid, wherein the protein and the polymer have opposite charges at a predetermined pH.

### Claim 11

A method for producing a lipid nanoparticle comprising:
a droplet forming step of mixing a protein selected from the antibody and the antibody fragment with the polymer to form a droplet; and
an encapsulation step of mixing the droplet and the lipid to encapsulate the droplet with the lipid.
